John Overdeck’s MoonLake Immunotherapeutics MLTX Stock Holding History

John Overdeck’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.4M	Buy	1,715,349 +593,037	+53%	+$10.8M	0.02%	743
2026 Q1	$20.9M	Buy	1,122,312 +337,501	+43%	+$5.59M	0.02%	918
2025 Q4	$10.3M	Buy	784,811 +330,543	+73%	+$3.9M	0.01%	1099
2025 Q3	$3.26M	Buy	+454,268	New	+$23.7M	﹤0.01%	1791
2025 Q2	–	Sell	-35,638	Closed	-$1.39M	–	3393
2025 Q1	$1.39M	Buy	+35,638	New	+$1.54M	﹤0.01%	1975
2024 Q1	–	Sell	-3,853	Closed	-$233K	–	3242
2023 Q4	$233K	Hold	3,853	–	–	﹤0.01%	2774
2023 Q3	$220K	Buy	+3,853	New	+$213K	﹤0.01%	2603
2023 Q1	–	Sell	-12,385	Closed	-$130K	–	3108
2022 Q4	$130K	Buy	+12,385	New	+$110K	﹤0.01%	2471

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

John Overdeck's MLTX Position: Q2 2026 in Review

John Overdeck increased its MoonLake Immunotherapeutics (MLTX) stake by 53% in Q2 2026, buying an estimated $10.8M and bringing the position to 1,715,349 shares worth $33.4M. The position accounts for 0.02% of the portfolio, ranked #743.

John Overdeck first reported a position in MLTX in Q4 2022 and has held it in 8 quarters since. 171 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

John Overdeck held 1,715,349 shares of MoonLake Immunotherapeutics worth $33.4M as of Q2 2026.
John Overdeck bought 593,037 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $10.8M.
MoonLake Immunotherapeutics made up 0.02% of John Overdeck's portfolio in Q2 2026, its #743 holding.
John Overdeck first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 8 quarters since.
171 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.